elranatamab
pfizer
['magnetismm-3', 'elranatamab']
elranatamab remains efficacious in #myeloma patients after 15 months of follow-up. if you want to know more about the clinical trial magnetismm-3, keep an eye out for our social media profiles. we will share a full interview with dr right after this session #eha2023 
A network of highly efficient, effective and sustainable myeloma and AL amyloidosis patient organisations across Europe